Hyundai Bioland현대바이오랜드

Hyundai Bioland's trailing profit has recovered sharply from 2025 and the share price is up strongly over three months, but the stock remains well below its 52-week high.

Hyundai Bioland makes natural bio-based ingredients for cosmetics, health foods, pharmaceutical raw materials and medical devices, and also distributes Nestlé Health Science brands such as Solgar in Korea. On a trailing basis to H1 2026 it reports revenue of about ₩141B, operating income of about ₩14.5B and net income of about ₩13.3B, against a much weaker 2025 when net income was only about ₩0.3B. At ₩4,405 the shares trade at about 9.9 times trailing earnings and 0.9 times book value, with no dividend listed.

What stands out

• Trailing net income of about ₩13.3B compares with ₩0.3B for full-year 2025, while trailing revenue of about ₩141B is above 2025's ₩131B.
• Trailing operating margin is 10.3% and net margin is 9.5%, but the 2024 operating margin was higher at 13.7%, so profitability has not returned to that level.
• The 3-month share price return is 31.3% and the 1-month return is 13.5%, while the 1-year return is -2.5%.
• The data shows a DCF-based fair value model with a base value of ₩6,109 and a range of ₩3,544 to ₩10,567; this is a model output, not a forecast or recommendation.
• Balance sheet figures look modest: liabilities to equity is 14.2%, cash is about ₩8.9B against borrowings of ₩6.0B, and trailing free cash flow is about ₩23.2B.
• Foreign ownership rose from 2.7% to 4.6% over about 60 days, while the 20-day flow data shows retail investors net selling about ₩1.0B.

What to watch

• Next earnings and the full-year 2026 results, since the recent gains rest on trailing figures that include strong 2026 periods.
• The June 2026 decision to increase short-term borrowings, and whether borrowings rise further relative to cash.
• The filings on large business group status and any IR follow-up, though the news feed for the company is currently empty so no press coverage is available in the data.